West Pharmaceutical Services INC: management transactions · United States · SEC (Form 4)

About West Pharmaceutical Services INC

West Pharmaceutical Services, Inc. (NYSE: WST) is a leading player in the healthcare supply chain in the United States. Headquartered in Exton, Pennsylvania, the company develops and supplies high-value solutions for the containment, packaging, and delivery of injectable medicines. Its customer base consists primarily of pharmaceutical companies, biotechnology firms, and drug developers, with a particularly strong position in sterile injectable and complex therapy applications. Founded in 1923, West has built its reputation over decades as a critical partner to the injectable drug industry, supported by expertise in materials science, precision engineering, and regulatory compliance. ([investor.westpharma.com](https://investor.westpharma.com/?utm_source=openai)) West operates through two main segments. The first, Proprietary Products, includes the company’s own branded components and systems for injectable drugs: high-value components, closure solutions, delivery devices, and standard products. The second, Contract-Manufactured Products, covers contract manufacturing activities, including work related to self-injection devices and other injectable delivery systems. This structure gives West a hybrid profile: it is both a manufacturer of essential components and a development/industrial partner for pharmaceutical customers. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai)) From a competitive standpoint, West occupies a niche but strategically important position. The company does not sell a drug itself; instead, it provides critical inputs that protect product integrity, support accurate dosing, and enable safe administration. That makes it deeply embedded in the pharma value chain and often difficult to replace, especially for high-specification injectable products. Recent product focus has included Westar®, Envision®, NovaPure®, Daikyo PLASCAP®, and SmartDose®, showing the breadth of its technology platform and its emphasis on higher-value offerings. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai)) Geographically, West has a global footprint, with operations centered in the United States and manufacturing/commercial capabilities across multiple regions. Recent disclosures highlighted the expansion of its Dublin facility to support high-volume injectable therapies, including diabetes and obesity, reinforcing exposure to large, secular growth markets in modern healthcare. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-expands-dublin-facility-support-high-volume-injectable?utm_source=openai)) Recent developments have been constructive. In 2025, West delivered solid results and raised guidance, and in the first quarter of 2026 it reported strong revenue and earnings growth while lifting full-year expectations again. The company also announced a planned divestiture of SmartDose® 3.5mL to AbbVie, alongside continued industrial investment and share repurchases. For French-speaking investors, West therefore stands out as a high-quality Healthcare & Pharma name listed on the U.S. NYSE market in the United States, with attractive exposure to injectable delivery systems, biologics, and long-term pharmaceutical outsourcing trends. ([investor.westpharma.com](https://investor.westpharma.com/news-releases/news-release-details/west-reports-fourth-quarter-and-full-year-2025-results?utm_source=openai))